On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...

A team of researchers led by Professor Ningling Kang, PhD, at The Hormel Institute, University of Minnesota, has published an ...

BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

Together with sustainability and raw material availability, gut health is one of the major areas of interest for global ...

Awareness about haemochromatosis - a genetic condition that also affects people from Scotland, Wales, England, and Brittany - ...

A research team at European XFEL and DESY has achieved a major advance in X-ray science by generating unprecedented ...

A father and son duo from Phoenix allegedly led the Monarrez Drug Trafficking Organization, moving fentanyl and meth from ...

Amylyx is progressing promising treatments for Wolfram Syndrome and Progressive Supranuclear Palsy with potential phase 3 trials. Learn more on AMLX stock here.

Amidst the wide variety of glycan modifications that are carried out in the Golgi apparatus, the addition of mannose 6-phosphate (M6P) to the N-linked glycans of lysosome-resident hydrolase enzymes ...